We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Gene Therapy for Prostate Cancer That Returns After Radiation Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00110526
Recruitment Status : Withdrawn (No participants met eligibility requirements)
First Posted : May 11, 2005
Last Update Posted : October 24, 2013
Sponsor:
Collaborator:
Information provided by (Responsible Party):

May 10, 2005
May 11, 2005
October 24, 2013
April 2005
April 2008   (Final data collection date for primary outcome measure)
maximum cytokine gene therapy level [ Time Frame: after 56 weeks, every 6 months up to 15 years ]
To study in a Phase I clinical trial the safety of intraprostatic injection of a replication incompetent adenovirus expressing hIL-12 in patients with radiorecurrent prostate cancer
To study in a Phase I clinical trial the safety of intraprostatic injection of a replication incompetent adenovirus expressing hIL-12 in patients with radiorecurrent prostate cancer
Complete list of historical versions of study NCT00110526 on ClinicalTrials.gov Archive Site
  • serum pro-inflammatory cytokines levels [ Time Frame: up to 15 years ]
    To assess serum levels of pro-inflammatory cytokines before and after vector injection and will continue every 3 days until normalized
  • To assess T cell responses pre and post-IL-12 treatment against prostate antigens [ Time Frame: Day 7 post vector injection ]
    Day 7,14,21 and 28 post vector injection
  • To assess T cell responses pre and post-IL-12 treatment against prostate antigens [ Time Frame: Day 14 post vector injection ]
    Day 7,14,21 and 28 post vector injection
  • To assess T cell responses pre and post-IL-12 treatment against prostate antigens [ Time Frame: Day 21 post vector injection ]
    Day 7,14,21 and 28 post vector injection
  • To assess T cell responses pre and post-IL-12 treatment against prostate antigens [ Time Frame: Day 28 post vector injection ]
    Day 7,14,21 and 28 post vector injection
  • To assess changes in PSA levels as a surrogate marker for prostate cancer following Ad.hIL-12 gene therapy [ Time Frame: 1 week after vector injection ]
    1,2,4,6 and 8 weeks after vector injection
  • To assess changes in PSA levels as a surrogate marker for prostate cancer following Ad.hIL-12 gene therapy [ Time Frame: 2 weeks after vector injection ]
    1,2,4,6 and 8 weeks after vector injection
  • To assess changes in PSA levels as a surrogate marker for prostate cancer following Ad.hIL-12 gene therapy [ Time Frame: 4 weeks after vector injection ]
    1,2,4,6 and 8 weeks after vector injection
  • To assess changes in PSA levels as a surrogate marker for prostate cancer following Ad.hIL-12 gene therapy [ Time Frame: 6 weeks after vector injection ]
    1,2,4,6 and 8 weeks after vector injection
  • To assess changes in PSA levels as a surrogate marker for prostate cancer following Ad.hIL-12 gene therapy [ Time Frame: 8 weeks after vector injection ]
    1,2,4,6 and 8 weeks after vector injection
  • To assess serum levels of pro-inflammatory cytokines before and after vector injection
  • To assess T cell responses pre and post-IL-12 treatment against prostate antigens
  • To assess changes in PSA levels as a surrogate marker for prostate cancer following Ad.hIL-12 gene therapy
Not Provided
Not Provided
 
Gene Therapy for Prostate Cancer That Returns After Radiation Therapy
Phase I Trial of Adenovirus- Mediated IL-12 Gene Transduction in Patients With Radiorecurrent Prostate Cancer
The purpose of this research study is to test a new treatment for prostate cancer. We have been exploring the use of cytokine (immune stimulating) gene therapy by directly injecting a virus which produces a cytokine called interleukin-12 (IL-12) into the prostate gland to control tumor growth. We propose to explore the use of adenovirus-mediated human interleukin-12 (Ad.hIL-12) in patients with recurrent non-metastatic prostate cancer following radiation therapy in a Phase I trial. Participants will be placed in rising dose groups with the primary endpoint of learning the maximum dose that can safely be given by injection directly into the prostate gland. Toxicity will be determined through physical examination, laboratory values, and blood levels of cytokines. Evidence of an immune response against prostate proteins will also be monitored. If the treatment works, the cancer will shrink or not grow. This will be monitored by prostate specific antigen (PSA) levels in the blood. However, we do not know if this treatment will be effective. If the PSA continues to rise after treatment, participants will be taken off study and offered other treatment. There is no compensation for participation in this research study. There will be no charge for the treatment with gene therapy or the monitoring associated with this research study. Monitoring will occur in a specially designated clinical research center.

Patients with radiorecurrent prostate cancer have few viable treatment options, both in terms of efficacy and morbidity. Local therapies fail even in highly selected patients due to locally advanced disease, microscopic metastases, and a worsening of the biology of cancer cells. Furthermore, attempts at salvage local treatments have the complications of incontinence, impotence and in some cases unremitting penile pain. Pre-clinical studies in a mouse model of prostate cancer have noted the potential benefit of adenovirus-mediated gene therapy to deliver IL-12 in this clinical scenario. This treatment was able to significantly growth suppress the injected tumor to prolong survival and reduce the number of pre-established metastases. The mechanisms underlying this activity involved both innate immunity (neutrophils and natural killer [NK] cells) and acquired immunity ( T cells) and enhanced expression of Fas to further sensitize Fas/Fas ligand (FasL) killing.

This is a Phase I study. Therefore, the primary objective is finding the Maximum Tolerated Dose. Within this realm will be monitoring of pro-inflammatory cytokines. Secondary aspects will involve correlating important mechanisms identified in the pre-clinical model: induction of T cells.

Interventional
Phase 1
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Prostatic Neoplasms
  • Neoplasm Recurrence, Local
Genetic: Ad.hIL-12
Ad.hIL-12 intraprostatic injection IND
Experimental: Ad.hIL-12
Intervention: Genetic: Ad.hIL-12
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
April 2008
April 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • A local recurrence of prostate cancer (in or next to gland) following treatment by radiation therapy (either external beam or seed implantation)
  • Rising PSA (Prostate Specific Antigen) on at least three occasions separated by two weeks
  • Ultrasound guided biopsy to diagnose recurrent disease within the prostate
  • No evidence of prostate cancer that has spread on bone scan or Computed Tomography (CT) scan
  • No hormone therapy at time of enrollment to the research study

Exclusion Criteria:

  • Radical prostatectomy for treatment of prostate cancer
  • Detectable spread of prostate cancer on bone or CT scan
  • Immunosuppressive medication within two months of the study
  • Acute infection (any bacterial, viral, fungal infection requiring specific therapy)
  • HIV disease
  • Other significant medical or psychiatric conditions which pose high risk for an investigational study
Sexes Eligible for Study: Male
40 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT00110526
GCO # 01-0595
A-11425
Yes
Not Provided
Not Provided
Simon Hall, Mount Sinai School of Medicine
Simon Hall
U.S. Army Medical Research and Materiel Command
Principal Investigator: Simon Hall, MD Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP